STOCK TITAN

Ginkgo Bioworks officer plans 2,200-share sale

Officer Che Austin has filed a Rule 144 notice to potentially sell 2,200 Class A shares of Ginkgo Bioworks Holdings, Inc.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. (DNA) has a notice of proposed sale under Rule 144 filed for officer Che Austin. The filing covers the potential sale of 2,200 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $16,038, against 55,383,808 Class A shares outstanding as of September 17, 2026. The shares derive from restricted stock vesting grants, and a prior sale of 2,200 Class A shares for $14,652 on August 17, 2026 is also disclosed.

Positive

  • None.

Negative

  • None.
Proposed shares to be sold 2,200 Class A shares Covered by the Rule 144 notice for Che Austin
Aggregate market value of proposed sale $16,038 Value of 2,200 Class A shares listed with Fidelity Brokerage Services LLC
Shares outstanding 55,383,808 Class A shares Outstanding as of September 17, 2026
Shares sold in prior 3 months 2,200 Class A shares Sold on August 17, 2026
Proceeds from prior sale $14,652 Total proceeds for 2,200 Class A shares sold on August 17, 2026
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Vesting financial
"Class A | 10/12/2022 | Restricted Stock Vesting | Issuer"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
attorney-in-fact regulatory
"as attorney-in-fact for Austin Che"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Ginkgo Bioworks (DNA)?

The filing discloses that officer Che Austin intends, under Rule 144, to potentially sell 2,200 Class A shares of Ginkgo Bioworks Holdings, Inc. through Fidelity Brokerage Services LLC, with an aggregate market value of $16,038 at the time of the notice.

How many Ginkgo Bioworks (DNA) shares are covered by this Rule 144 notice?

The notice covers a potential sale of 2,200 Class A shares of Ginkgo Bioworks Holdings, Inc. The filing lists these shares in connection with a proposed sale through Fidelity Brokerage Services LLC under Rule 144.

What is the disclosed market value of the DNA shares in this Form 144?

The aggregate market value of the 2,200 Class A shares covered by the Form 144 is reported as $16,038. This figure is tied to the proposed sale amount listed with Fidelity Brokerage Services LLC.

How many Ginkgo Bioworks (DNA) shares were outstanding as of the date in the filing?

The filing states that 55,383,808 Class A shares of Ginkgo Bioworks Holdings, Inc. were outstanding as of September 17, 2026. This provides a baseline figure relative to the 2,200 shares covered by the notice.

What prior sales of Ginkgo Bioworks (DNA) shares by Che Austin are disclosed?

The filing reports that on August 17, 2026, 2,200 Class A shares of Ginkgo Bioworks Holdings, Inc. were sold for total proceeds of $14,652. This transaction falls within the three-month look-back period referenced in the notice.

How were the Ginkgo Bioworks (DNA) shares in this Form 144 acquired?

The shares are shown as originating from restricted stock vesting events. The filing lists multiple vesting dates in October and November 2022, with the issuer identified as the source and the form of payment described as Compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading